Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3761-3769

  Jounaidi, Y ^a   Waxman, D J ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 REDUCTASE; PRODRUG; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL HYPOXIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE THERAPY; GENETIC TRANSDUCTION; GLIOSARCOMA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR; TUMOR GROWTH;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CELL DIVISION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOSARCOMA; HUMANS; MICE; MICE, SCID; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASM TRANSPLANTATION; OXYGEN; PRODRUGS; RETROVIRIDAE; TIME FACTORS; TRANSDUCTION, GENETIC; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0034660849     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
2. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
3. Bioreductive agents: A clinical update
4. Tirapazamine: Laboratory data relevant to clinical activity
5. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: A direct role for NADPH:cytochrome P450 oxidoreductase
6. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
7. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069
8. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical
9. Dual action of tirapazamine in the induction of DNA strand breaks
10. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro
11. Enzymology of tirapazamine metabolism: A review
12. Adaptation of human tumor cells to tirapazamine under aerobic conditions: Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity
13. Initial characterization of the major mouse cytochrome P450 enzyme: Involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-tenzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233. WIN 59075)
14. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233. WIN 59075) by mouse liver
15. Oxygen and xenobiotic reductase activities of cytochrome P450
16. The metabolism and mode of action of gentian violet
17. Oxazaphosphorine-specific acquired cellular resistance
18. Cytochrome P450-based cancer gene therapy: Recent advances and future prospects
19. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
20. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
21. An oncolytic viral mutant that delivers the CYP2BI transgene and augments cyclophosphamide chemotherapy
22. Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles
23. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes
24. Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man
25. Expression of cytochromes P450 in human breast tissue and tumors
26. Cytochrome P450 CYP3A in human renal cell cancer
27. Potentiation of cytozhrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene
28. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy
29. Human NADPH-P450 oxidoreductase: Complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7
30. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helperfree packaging cell line
31. Production of high-titer helper-free retroviruses by transient transfection
32. Human tumor models in the severe combined immune deficient (scid) mouse
33. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours
34. Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect."
35. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
36. Interaction of anticancer drugs with hepatic monooxygenase enzymes
37. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
38. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines
39. Cytochrome P450 2B1-mediated one-electron reduction of Adriamycin: A study with rat liver microsomes and purified enzymes
40. One-electron reduction of mitomycin C by rat liver: Role of cytochrome P-450 and NADPH-cytochrome P-450 reductase
41. The role of the bystander effect in suicide gene therapy
42. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts
43. The in situ tumour response to combinations of cyclophosphamide and tirapazamine
44. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice
45. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmaco-kinetically guided dose-escalation strategy in a Phase I trial
46. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines
47. Diversity of penetration of anti-cancer agents into solid tumours
48. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids
49. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug
50. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase
51. Transfection of human cytochrome P-450 reductase cDNA and its effect on the sensitivity to toxins
52. Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase
53. The experimental development of bioreductive drugs and their role in cancer therapy
54. Hypoxia response elements
55. Targeting gene expression to hypoxic tumor cells
56. Development of a hypoxia-responsive vector for tumor-specific gene therapy
57. The macrophage: A novel system to deliver gene therapy to pathological hypoxia